{
  "source": "PA-Notification-Voxzogo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1381-4\nProgram Prior Authorization/Notification\nMedication Voxzogo™ (vosoritide)\nP&T Approval Date 3/2022, 3/2023, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nVoxzogo (vosoritide) is a C type natriuretic peptide (CNP) analog indicated to increase linear\ngrowth in pediatric patients with achondroplasia with open epiphyses. This indication is\napproved under accelerated approval based on an improvement in annualized growth velocity.\nContinued approval for this indication may be contingent upon verification and description of\nclinical benefit in confirmatory trial(s).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Voxzogo will be approved based on all of the following criteria:\na. Diagnosis of achondroplasia\n-AND-\nb. Patient is less than 18 years of age\n-AND-\nc. Patient has open epiphyses\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Voxzogo will be approved based on the following criterion:\na. Documentation of positive clinical response to Voxvogo therapy\n-AND-\nb. Patient has open epiphyses\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2024 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and medical necessity may be in place.\n4. References:\n1. Voxzogo [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; October 2023.\nProgram Prior Authorization/Notification - Voxzogo (vosoritide)\nChange Control\n3/2022 New program\n3/2023 Annual review with n",
    " [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; October 2023.\nProgram Prior Authorization/Notification - Voxzogo (vosoritide)\nChange Control\n3/2022 New program\n3/2023 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n12/2023 Updated background and coverage criteria with expanded indication in\npediatric patients of all ages. Updated reference.\n12/2024 Annual review. Added requirement that patient has open epiphyses to\nreauthorization criteria.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}